Latest Insider Transactions at Editas Medicine, Inc. (EDIT)
This section provides a real-time view of insider transactions for Editas Medicine, Inc. (EDIT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Editas Medicine, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Editas Medicine, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 03
2022
|
Bruce Eaton EVP, CBO AND CTO |
SELL
Open market or private sale
|
Direct |
1,123
-1.69%
|
$12,353
$11.54 P/Share
|
|
Jun 02
2022
|
Gilmore Neil O'Neill CEO |
BUY
Grant, award, or other acquisition
|
Direct |
86,655
+50.0%
|
-
|
|
May 09
2022
|
Bruce Eaton EVP, CBO AND CTO |
SELL
Open market or private sale
|
Direct |
297
-0.44%
|
$3,861
$13.11 P/Share
|
|
Apr 01
2022
|
Bruce Eaton EVP, CBO AND CTO |
SELL
Open market or private sale
|
Direct |
1,258
-1.85%
|
$23,902
$19.64 P/Share
|
|
Mar 03
2022
|
Michelle Robertson EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
767
-0.9%
|
$13,039
$17.33 P/Share
|
|
Mar 03
2022
|
Bruce Eaton EVP, CBO AND CTO |
SELL
Open market or private sale
|
Direct |
403
-0.59%
|
$6,851
$17.33 P/Share
|
|
Feb 10
2022
|
Michelle Robertson EVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
53,499
+38.64%
|
-
|
|
Feb 10
2022
|
Mark S Shearman EVP, CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
31,709
+30.14%
|
-
|
|
Feb 10
2022
|
Bruce Eaton EVP, CBO AND CTO |
BUY
Grant, award, or other acquisition
|
Direct |
37,593
+35.34%
|
-
|
|
Feb 08
2022
|
Bruce Eaton EVP, CBO AND CTO |
SELL
Open market or private sale
|
Direct |
302
-0.96%
|
$5,134
$17.63 P/Share
|
|
Jan 11
2022
|
Michelle Robertson EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,744
-5.25%
|
$43,600
$25.7 P/Share
|
|
Jan 03
2022
|
James C Mullen CEO |
SELL
Open market or private sale
|
Direct |
18,252
-19.39%
|
$474,552
$26.95 P/Share
|
|
Dec 22
2021
|
James C Mullen CEO |
BUY
Grant, award, or other acquisition
|
Direct |
36,477
+27.92%
|
-
|
|
Dec 22
2021
|
Michelle Robertson EVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,471
+11.87%
|
-
|
|
Dec 22
2021
|
Mark S Shearman EVP, CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
9,084
+17.86%
|
-
|
|
Dec 22
2021
|
Lisa Anne Michaels EVP/Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,243
+15.76%
|
-
|
|
Dec 22
2021
|
Bruce Eaton EVP, CBO AND CTO |
BUY
Grant, award, or other acquisition
|
Direct |
3,472
+9.93%
|
-
|
|
Nov 12
2021
|
Lisa Anne Michaels EVP/Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,568
-7.84%
|
$59,584
$38.33 P/Share
|
|
Nov 09
2021
|
Bruce Eaton EVP, CBO AND CTO |
SELL
Open market or private sale
|
Direct |
287
-1.01%
|
$11,480
$40.61 P/Share
|
|
Oct 18
2021
|
James C Mullen CEO |
SELL
Open market or private sale
|
Direct |
13,805
-19.31%
|
$524,590
$38.03 P/Share
|
|
Sep 30
2021
|
James C Mullen CEO |
BUY
Grant, award, or other acquisition
|
Direct |
36,478
+33.79%
|
-
|
|
Aug 09
2021
|
Bruce Eaton EVP, CBO AND CTO |
SELL
Open market or private sale
|
Direct |
287
-0.42%
|
$16,359
$57.17 P/Share
|
|
Aug 09
2021
|
Michelle Robertson EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-8.0%
|
$150,000
$60.0 P/Share
|
|
Aug 09
2021
|
Michelle Robertson EVP, CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+7.41%
|
$75,000
$30.65 P/Share
|
|
Jun 28
2021
|
Michelle Robertson EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-8.0%
|
$125,000
$50.0 P/Share
|
|
Jun 28
2021
|
Michelle Robertson EVP, CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+7.41%
|
$75,000
$30.65 P/Share
|
|
Jun 14
2021
|
Mark S Shearman EVP, CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
32,701
+50.0%
|
-
|
|
Mar 03
2021
|
Jessica Hopfield Director |
BUY
Open market or private purchase
|
Direct |
5,800
+20.35%
|
$261,000
$45.51 P/Share
|
|
Mar 02
2021
|
James C Mullen CEO |
BUY
Open market or private purchase
|
Direct |
25,000
+41.67%
|
$1,150,000
$46.27 P/Share
|
|
Mar 02
2021
|
Michelle Robertson EVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,303
+26.39%
|
-
|
|
Feb 09
2021
|
Cynthia Collins CEO |
SELL
Open market or private sale
|
Direct |
1,262
-2.8%
|
$83,292
$66.65 P/Share
|
|
Jan 12
2021
|
Michelle Robertson EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,568
-7.84%
|
$122,304
$78.27 P/Share
|
|
Dec 15
2020
|
Charles Albright EVP/Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-10.39%
|
$630,000
$63.66 P/Share
|
|
Dec 15
2020
|
Charles Albright EVP/Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+22.27%
|
$160,000
$16.51 P/Share
|
|
Dec 09
2020
|
Charles Albright EVP/Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-28.65%
|
$450,000
$45.0 P/Share
|
|
Dec 09
2020
|
Charles Albright EVP/Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+22.27%
|
$160,000
$16.51 P/Share
|
|
Dec 07
2020
|
Charles Albright EVP/Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-44.54%
|
$800,000
$40.02 P/Share
|
|
Dec 07
2020
|
Charles Albright EVP/Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+30.81%
|
$320,000
$16.51 P/Share
|
|
Nov 09
2020
|
Charles Albright EVP/Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
228
-0.91%
|
$7,068
$31.21 P/Share
|
|
Nov 09
2020
|
Lisa Anne Michaels EVP/Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Oct 15
2020
|
Charles Albright EVP/Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-10.66%
|
$93,000
$31.39 P/Share
|
|
Feb 08
2015
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,020,407
+40.39%
|
-
|
|
Feb 08
2015
|
Viking Global Investors LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,709,401
+50.0%
|
-
|
|
Feb 08
2015
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,020,407
+13.85%
|
-
|
|
Feb 08
2015
|
Viking Global Investors LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,709,401
+50.0%
|
-
|